Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics, Inc. (PLRX)
:PLRX
PLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $16.52
Previous CloseN/A
Volume34.91K
Average Volume (3M)1.59M
Market Cap
$92.08M
Enterprise Value$505.92M
Total Cash (Recent Filing)-$4.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 12, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding61,386,276
10 Day Avg. Volume1,059,982
30 Day Avg. Volume1,592,062
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)52.32
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap5.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.47
Forecast
1Y Price Target
$5.25Price Target Upside254.73% Upside
Rating ConsensusHold
Number of Analyst Covering13
---
Pliant Therapeutics News
PremiumCompany Announcements
Pliant Therapeutics Adopts Stockholder Rights Agreement
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyPLN-101095 showed a partial response rate of 50% at the highest dose cohort.
Financial PositionPLRX reported $357M cash as of YE24 and $30M in debt principal.
Program AdvancementThe first-in-human Phase 1 study is now enrolling patients to the fourth of five cohorts, demonstrating PLN-101095's anti-tumor activity when combined with pembrolizumab in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.
Bears Say
Adverse EventsSome patients in the bexotegrast groups with IPF-related serious adverse events experienced accelerated progression of IPF, with cases of rapid declines in pulmonary function.
Clinical Program DiscontinuationPLRX announced discontinuation of the BEACON-IPF study due to an imbalance in adverse events in the active vs placebo groups.
UncertaintyThe discontinuation of the BEACON-IPF study creates uncertainty and makes it challenging to have conviction in the stock without more clarity.
---
Ownership Overview
4.75% Insiders
18.72% Mutual Funds
0.33% Other Institutional Investors
64.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLRX FAQ
What was Pliant Therapeutics, Inc.’s price range in the past 12 months?
Pliant Therapeutics, Inc. lowest stock price was $1.10 and its highest was $16.52 in the past 12 months.
What is Pliant Therapeutics, Inc.’s market cap?
Pliant Therapeutics, Inc.’s market cap is $92.08M.
When is Pliant Therapeutics, Inc.’s upcoming earnings report date?
Pliant Therapeutics, Inc.’s upcoming earnings report date is May 12, 2025 which is in 19 days.
How were Pliant Therapeutics, Inc.’s earnings last quarter?
Pliant Therapeutics, Inc. released its earnings results on Mar 03, 2025. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.956 by $0.136.
Is Pliant Therapeutics, Inc. overvalued?
According to Wall Street analysts Pliant Therapeutics, Inc.’s price is currently Undervalued.
Does Pliant Therapeutics, Inc. pay dividends?
Pliant Therapeutics, Inc. does not currently pay dividends.
What is Pliant Therapeutics, Inc.’s EPS estimate?
Pliant Therapeutics, Inc.’s EPS estimate is -0.77.
How many shares outstanding does Pliant Therapeutics, Inc. have?
Pliant Therapeutics, Inc. has 61,386,276 shares outstanding.
What happened to Pliant Therapeutics, Inc.’s price movement after its last earnings report?
Pliant Therapeutics, Inc. reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.956. Following the earnings report the stock price went down -2.174%.
Which hedge fund is a major shareholder of Pliant Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PLRX
---
Pliant Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.25 (254.73% Upside)
$5.25 (254.73% Upside)
Blogger Sentiment
Bullish
PLRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 45.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.09%
12-Months-Change
Fundamentals
Return on Equity
-54.09%
Trailing 12-Months
Asset Growth
-22.49%
Trailing 12-Months
Company Description
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
---
PLRX Stock 12 Month Forecast
Average Price Target
$5.25
▲(254.73% Upside)
Technical Analysis
Best Analysts Covering PLRX
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-20.65%
reiterated a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -20.65% per trade.
---